Selective ghrelin (GHS-R1a) receptor agonist. Drives a clean GH pulse without significant cortisol, prolactin or ACTH release.
Reference facts
- Also known as
- NNC 26-1095
- Category
- Growth Hormone & Ghrelin
- Mechanism of action
- Selective ghrelin (GHS-R1a) receptor agonist. Drives a clean GH pulse without significant cortisol, prolactin or ACTH release.
- Targets
- GHS-R1a
- Indications under research or approved
- Off-label research (combined with CJC-1295 for synergistic GH pulse)
- Regulatory status (reference entry)
- Not FDA-approved (Phase 2 for post-operative ileus, discontinued)
- Half-life
- ~2 hours
- Sequence notes
- Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH2. Aib (α-aminoisobutyric acid), D-amino acids and C-terminal amide make it non-natural.
- Molecular weight (Da)
- 712
- Originator / sponsor
- Originally Novo Nordisk
- First reported
- 1998
Primary References
Explore research articles about Ipamorelin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.